Coherus BioSciences, Inc. is a commercial-stage oncology company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. Its commercial product, LOQTORZI (toripalimab-tpzi), is a programmed death receptor-1 (PD-1) monoclonal antibody that blocks PD-1 ligands PD-L1 and PD-L2 with high potency. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in three ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is a cytolytic anti-CCR8 antibody which is in Phase I study in patients with advanced solid tumors. CHS-1000 is a humanized Fc-modified IgG1 monoclonal antibody targeting ILT4.